Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds

Autor: Gantz, Ira, Sokolova, Liubov, Jain, Lokesh, Iredale, Carol, O'Neill, Edward A., Wei, Ziwen, Lam, Raymond, Suryawanshi, Shailaja, Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Zdroj: In Clinical Therapeutics October 2017 39(10):2024-2037
Databáze: ScienceDirect
Externí odkaz: